Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women

Circulation

Volumn 108, Issue 7, 2003, Pages 808-813

  Wakatsuki, Akihiko ^a   Okatani, Yuji ^b   Ikenoue, Nobuo ^b   Shinohara, Koichi ^b   Watanabe, Kazushi ^b   Fukaya, Takao ^b  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

Hormones; Lipoproteins; Women

Indexed keywords

CONJUGATED ESTROGEN; LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OXIDATION; PARTICLE SIZE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); ESTRONE; FEMALE; HUMANS; JAPAN; LIPOPROTEINS, LDL; MIDDLE AGED; OXIDANTS; OXIDATION-REDUCTION; PARTICLE SIZE; POSTMENOPAUSE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0042388282     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000084552.54277.64     Document Type: Article

References (35)

1. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclasses patterns and the risk of myocardial infarction. JAMA. 1988;260:1917-1921.
2. Tribble DL, Holl LG, Wood PD, et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93:189-199.
3. Ikenoue N, Wakatsuki A, Okatani Y. Small low-density lipoprotein particles in women with natural or surgically induced menopause. Obstet Gynecol. 1999;93:566-570.
4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
5. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
7. Wakatsuki A, Ikenoue N, Sagara Y. Effect of estrogen on the size of low-density lipoprotein particles in postmenopausal women. Obstet Gynecol. 1997;90:22-25.
8. Wakatsuki A, Ikenoue N, Sagara Y. Estrogen-induced small low-density lipoprotein particles in postmenopausal women. Obstet Gynecol. 1998;91:234-240.
9. Wakatsuki A, Ikenoue N, Okatani Y, et al. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol. 2001;37:425-430.
10. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
11. Lobo RA, Bush T, Carr BR, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001;76:13-24.
12. Allain CC, Poon LS, Chan CG, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
13. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest. 1955;34:1346-1353.
14. Gambert P, Bouzenard-Gambert C, Athias A, et al. Human low density lipoprotein subfractions separated by gradient gel electrophoresis: composition, distribution, and alterations induced by cholesteryl ester transfer protein. J Lipid Res. 1990;31:1199-1210.
15. Lagrost L, Gandjini H, Athias A, et al. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb. 1993;13:815-825.
16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
17. Esterbauer H, Striegl G, Puhl H, et al. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6:67-75.
18. Ma PT, Yamamoto T, Goldstein JT, et al. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha ethinyl estradiol. Proc Natl Acad Sci U S A. 1986;83:792-796.
19. Wakatsuki A, Ikenoue N, Sagara Y. Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in post-menopausal women. Maturitas. 1998;28:229-234.
20. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B-12B.
21. McNamara JR, Jenner JL, Li Z, et al. Change in LDL particle size is associated with changes in plasma triglyceride concentration. Arterioscler Thromb. 1992;12:1284-1290.
22. Wakatsuki A, Ikenoue N, Okatani Y, et al. Lipid transfer reactions and lipid composition of low-density lipoprotein particles in post-menopausal women receiving estrogen. Obstet Gynecol. 1999;94:492-497.
23. Wakatsuki A, Ikenoue N, Okatani Y, et al. Lipolytic enzyme effect on small low-density lipoprotein particles in women treated with estrogen. Obstet Gynecol. 2001;97:333-337.
24. Mackness MI, Abbott C, Arrol S, et al. The role of high-density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993;294:829-834.
25. Hwang J, Peterson H, Hodis HN, et al. Ascorbic acid enhances 17 beta-estradiol-mediated inhibition of oxidized low density lipoprotein formation. Atherosclerosis. 2000;150:275-284.
26. Arteaga E, Rojas A, Villaseca P, et al. The effect of 17beta-estradiol and alpha-tocopherol on the oxidation of LDL cholesterol from post-menopausal women and the minor effect of gamma-tocopherol and melatonin. Menopause. 2000;7:112-116.
27. Sack MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269-270.
28. Mc Manus J, Mc Eneny J, Thompson W, et al. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in post-menopausal women. Atherosclerosis. 1997;135:73-81.
29. Sanchez-Quesada JL, Camacho M, Anton R, et al. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis. 2003;166:261-270.
30. Wakatsuki A, Okatani Y, Ikenoue N, et al. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation. 2002;106:1771-1776.
31. Tchernof A, Lamarche B, Prud'Homme D, et al. The dense LDL pheno-type: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care. 1996;19:629-637.
32. Mykkanen L, Haffner SM, Rainwater DL, et al. Relationship of LDL size to insulin sensitivity in normoglycemic men. Arterioscler Thromb Vasc Biol. 1997;17:1447-1453.
33. Brussaard HE, Gevers Leuven JA, Frolich M, et al. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia. 1997;40:843-849.
34. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
35. Ferrara A, Quesenberry CP, Karter AJ, et al. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation. 2003;107:43-48.